BANK • PEŁNY PODGLĄD

geografia: Psilocybin

Bezużyteczne Fakty • wikipedia-seeded

candidateneeds-reviewC 91%

Fakt używany przez pipeline

As of September 2026, complete submission of psilocybin for treatment-resistant depression is expected in the fourth quarter of 2026 and commercial launch for this indication is anticipated in the first half of 2027.

Pełniejszy materiał źródłowy / excerpt

Psilocybin, also known as 4-phosphoryloxy-N,N-dimethyltryptamine (4-PO-DMT), is a naturally occurring tryptamine alkaloid and investigational drug found in more than 200 species of mushrooms, with hallucinogenic and serotonergic effects. Effects include euphoria, changes in perception, a distorted sense of time, and perceived spiritual experiences. Psilocin is the metabolite of psilocybin. The compound psilocybin itself is biologically inactive but quickly converted by the body to psilocin. Psilocybin is transformed into psilocin by dephosphorylation mediated via phosphatase enzymes. Psilocin is chemically related to the neurotransmitter serotonin and acts as a non-selective agonist of the serotonin receptors. Activation of one serotonin receptor, the serotonin 5-HT2A receptor, is specifically responsible for the hallucinogenic effects of psilocin and other serotonergic psychedelics. Psilocybin is usually taken orally. By this route, its onset is about 20 to 50 minutes, peak effects occur in about 1 to 2 hours, and its duration is about 4 to 6 hours. Psilocybin mushrooms were used ritualistically in pre-Columbian Mexico, but claims of their widespread ancient use are largely exagg…

Kategoria: geografia

Rodzina: geografia

Jakość źródła: 65/100

Próby weryfikacji: 3

Notatka fact-checku: Fact-check 3.0-content-aware: no sufficient claim-bound corroboration after 3 healthy attempts. Scope=verify the factual claim. Required independent sources=2; stored evidence groups=0. Provider/API errors did not consume attempts. | Fact-check 4.3.2: research wznowiony bez zdejmowania HOLD. Poprzednia metoda: factcheck-300-content-aware.

ŹRÓDŁA I DOWODY

6 zapisanych źródeł

Center for Open Sciencepomocniczeniezależne

Evidence: 29 • authority: 88

Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression”. This commentary critically examines the interpretation and analytic choices in Goodwin et al.’s (2026) analysis of therapeutic alliance in psilocybin treatment for treatment-resistant depression. While the authors conclude that alliance did not meaningfully contribute to treatment efficacy, we argue that this interpretation is not supported by the reported results, which are, in addition, shaped by methodological decisions that obscure relevant effects. By contextualizing the observed associations, clarifying the logic of mediatio…

Otwórz źródło ↗

Wileypomocniczeniezależne

Evidence: 29 • authority: 88

Psilocybin shows mixed results for patients with treatment‐resistant depression. Patients with treatment‐resistant depression who received psilocybin‐assisted psychotherapy showed clinically meaningful improvement in depressive symptoms relative to placebo, a Phase 2b trial has found. However, the study did not show a significant effect on the primary outcome of treatment response 6 weeks after the first of two doses of psilocybin. Study results were published online March 18, 2026 in JAMA Psychiatry .

Otwórz źródło ↗

Springer Science and Business Media LLCpomocniczeniezależne

Evidence: 26 • authority: 88

A Two-Threshold Model of Psilocybin Response Explains Variability in Psychedelic-Assisted Therapy for Treatment-Resistant Depression. Abstract The COMP006 Phase 3 trial showed that 39% of patients with treatment-resistant depression (TRD) respond to a single 25 mg dose of psilocybin, while 61% do not — at identical dose, protocol, and pharmacological exposure. No mechanistic explanation for this heterogeneity has been established. Here we propose and validate a two-threshold model in which the psilocybin dose-response landscape is governed by two qualitatively distinct transitions: a universal first threshold at Dc1 = 18 ±1 mg and an individual-dependent second threshold near Dc2 ≈21–30 mg.…

Otwórz źródło ↗

Springer Science and Business Media LLCpomocniczeniezależne

Evidence: 20 • authority: 80

The psychedelic compound psilocybin may ‘reset’ the brain to help manage treatment-resistant major depression

Otwórz źródło ↗

Royal Pharmaceutical Societypomocniczeniezależne

Evidence: 20 • authority: 80

Psilocybin may be effective for treatment-resistant depression

Otwórz źródło ↗

Wikipediapomocnicze

Evidence: — • authority: 54

Otwórz źródło ↗